AMPH Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 109097 min ago

@ $55.32

Išleistas: 13 vas. 2024 @ 18:06

Grąža: -25.68%

Ankstesnis signalas: vas. 13 - 16:30

Ankstesnis signalas: Pirkimas

Grąža: 0.69 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	263 601
Vidutinė apimtis	419 558
Rinkos kapitalizacija	2.01B
EPS	$0 ( 2024-02-27 )
Kita pelno data	( $0 ) 2024-05-07
Last Dividend	$0.300 ( 2010-06-11 )
Next Dividend	$0 ( N/A )
P/E	15.81
ATR14	$0.0230 (0.06%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Petersen Floyd F.	Sell	500	Common Stock
2024-03-15	Zhang Jack Y.	Buy	722 046	Common Stock
2024-03-15	Zhang Jack Y.	Sell	408 721	Common Stock
2024-03-17	Zhang Jack Y.	Sell	15 768	Common Stock
2024-03-15	Zhang Jack Y.	Buy	310 930	Common Stock

INSIDER POWER
-2.74
Last 100 transactions
Buy: 1 574 905 \| Sell: 1 727 474

Tūris Koreliacija

Ilgas: -0.42 (neutral)

Trumpas: 0.49 (neutral)

Signal:(32.94) Neutral

Amphastar Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
LMNR	0.96
PDFS	0.955
RCEL	0.953
GEOS	0.953
ALTR	0.951
VTYX	0.951
ERII	0.95
SLMBP	0.95
PANL	0.946
ANSS	0.945

10 Labiausiai neigiamai susiję koreliacijos
CSSEP	-0.95
NAKD	-0.95
ALXO	-0.95
MICS	-0.95
BLUE	-0.946
CBNK	-0.944
PMVP	-0.943
CMLS	-0.94
BWB	-0.94
FGBI	-0.939

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Amphastar Pharmaceuticals Koreliacija - Valiuta/Žaliavos

-0.59
( weak negative )

-0.35
( neutral )

0.00
( neutral )

-0.30
( neutral )

0.08
( neutral )

0.45
( neutral )

Amphastar Pharmaceuticals Finansinės ataskaitos

Annual	2023
Pajamos:	$644.40M
Bruto pelnas:	$343.97M (53.38 %)
EPS:	$2.85

FY	2023
Pajamos:	$644.40M
Bruto pelnas:	$343.97M (53.38 %)
EPS:	$2.85

FY	2022
Pajamos:	$498.99M
Bruto pelnas:	$248.86M (49.87 %)
EPS:	$1.880

FY	2021
Pajamos:	$437.77M
Bruto pelnas:	$199.74M (45.63 %)
EPS:	$1.350

Financial Reports:

No articles found.

Amphastar Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Amphastar Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.09 - Potential for dividend initiation, but uncertain (18.12%)

Information

First Dividend	$0.300	2009-06-11
Last Dividend	$0.300	2010-06-11
Next Dividend	$0	N/A
Payout Date	2010-06-30
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.600	--
Avg. Dividend % Per Year	0.00%	--
Score	2.66	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.09
Div. Directional Score	7.14	--

Next Divdend (Est)
(2025-03-28)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

2.66

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.213	1.500	5.73	8.60	[0 - 0.5]
returnOnAssetsTTM	0.0909	1.200	6.97	8.36	[0 - 0.3]
returnOnEquityTTM	0.232	1.500	8.53	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.17	0.800	4.14	3.31	[1 - 3]
quickRatioTTM	1.660	0.800	4.94	3.95	[0.8 - 2.5]
cashRatioTTM	0.641	1.500	7.55	10.00	[0.2 - 2]
debtRatioTTM	0.392	-1.500	3.46	-5.19	[0 - 0.6]
interestCoverageTTM	9.50	1.000	7.59	7.59	[3 - 30]
operatingCashFlowPerShareTTM	3.83	2.00	8.72	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.03	2.00	8.48	10.00	[0 - 20]
debtEquityRatioTTM	0.928	-1.500	6.29	-9.43	[0 - 2.5]
grossProfitMarginTTM	0.541	1.000	4.32	4.32	[0.2 - 0.8]
operatingProfitMarginTTM	0.294	1.000	6.12	6.12	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.309	1.000	9.39	9.39	[0.2 - 2]
assetTurnoverTTM	0.426	0.800	-0.494	-0.395	[0.5 - 2]
Total Score				10.19

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	14.33	1.000	8.65	0	[1 - 100]
returnOnEquityTTM	0.232	2.50	9.06	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.03	2.00	8.99	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	3.83	2.00	8.72	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.191	1.500	-2.06	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.285	1.000	5.38	0	[0.1 - 0.5]
Total Score				4.09

Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.